No connection

Search Results

AKAN vs INM

AKAN
Akanda Corp.
BEARISH
Price
$0.82
Market Cap
$1.7M
Sector
Healthcare
AI Confidence
95%
INM
InMed Pharmaceuticals Inc.
BEARISH
Price
$0.72
Market Cap
$2.4M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
AKAN
0.01
INM
--
Forward P/E
AKAN
--
INM
-0.11
P/B Ratio
AKAN
0.04
INM
0.21
P/S Ratio
AKAN
2.06
INM
0.53
EV/EBITDA
AKAN
0.55
INM
0.57

Profitability

Gross Margin
AKAN
24.91%
INM
29.73%
Operating Margin
AKAN
-443.84%
INM
-258.57%
Profit Margin
AKAN
-266.31%
INM
-170.07%
ROE
AKAN
-60.86%
INM
-97.2%
ROA
AKAN
-28.69%
INM
-49.77%

Growth

Revenue Growth
AKAN
--
INM
-26.2%
Earnings Growth
AKAN
--
INM
--

Financial Health

Debt/Equity
AKAN
0.12
INM
0.06
Current Ratio
AKAN
1.25
INM
5.94
Quick Ratio
AKAN
0.89
INM
4.85

Dividends

Dividend Yield
AKAN
--
INM
--
Payout Ratio
AKAN
0.0%
INM
0.0%

AI Verdict

AKAN BEARISH

AKAN exhibits severe financial distress, evidenced by a Piotroski F-Score of 3/9 (indicating weak operational health) and a lack of an Altman Z-Score, which raises red flags for potential bankruptcy risk. The company is unprofitable with negative margins across all key metrics, including a staggering -266.31% profit margin and -60.86% ROE. Despite a low Price/Book of 0.04 and a Graham Number of $281.01, the stock trades at $0.82—well below fair value—due to extreme operational failure and lack of sustainable growth. The 52-week price range shows a collapse from $46.45 to $0.81, reflecting a 100% decline over five years and confirming deep investor skepticism.

Strengths
Graham Number suggests a defensive fair value of $281.01
Low Price/Book ratio (0.04) indicates potential undervaluation on asset basis
Debt/Equity ratio of 0.12 suggests conservative capital structure
Risks
Piotroski F-Score of 3/9 signals weak financial health and operational inefficiency
Negative profit, operating, and return metrics across the board (ROE: -60.86%, ROA: -28.69%)
No revenue or earnings growth data available, suggesting stagnation or collapse
INM BEARISH

The company exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness across nearly all fundamental health dimensions. While the current ratio is high (5.94), this is offset by a catastrophic profit margin of -170.07% and declining year-over-year revenue growth of -26.20%. The stock is in a clear long-term death spiral, with a 5-year price change of -100% and a technical trend score of 0/100. Without a pivot to profitability or a significant capital infusion, the business model appears unsustainable.

Strengths
Very low Debt/Equity ratio (0.06) indicating minimal long-term debt burden
Strong short-term liquidity with a Current Ratio of 5.94
Positive Gross Margin (29.73%) suggesting the core product has some inherent value
Risks
Critical financial health as evidenced by a 1/9 Piotroski F-Score
Severe operational inefficiency with an Operating Margin of -258.57%
Negative revenue growth (-26.20% YoY) indicating shrinking market share or demand

Compare Another Pair

AKAN vs INM: Head-to-Head Comparison

This page compares Akanda Corp. (AKAN) and InMed Pharmaceuticals Inc. (INM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile